Table 4 Incremental cost-effectiveness ratio per QALY gained
From: Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia
| Â | FC II | FC III |
|---|---|---|
sildenafil vs beraprost | sildenafil vs beraprost | |
Incremental Cost (USD) | 1769 | 4252 |
Incremental QALYs | 0.57 | 1.50 |
ICER per QALY gained (USD) | 3098 | 2827 |